tiprankstipranks
NewsSmart PortfolioMarkets
Top Stocks
Daily Feeds
Tools
Calendars
Top Smart Score Stocks
New
Analysts' Top StocksInsiders' Hot Stocks
Popular
Trending Stocks
Research Tools
My Portfolio
My Watchlists
Profile & Performance
OverviewMy HoldingsMy Portfolio AnalysisCrowd Insights
Smart Portfolio
Top Smart Score Stocks
New
Analysts' Top StocksInsiders' Hot Stocks
Popular
Trending Stocks
Top Stocks
Find & Follow Experts
Top Lists
My ExpertsExpert CenterTop Firms
Top Experts
Categories
Trending Topics
HomeMarket NewsTipRanks LabsIdeas & InsightsStock Analysis
News
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
About us
About TipRanksReviewsContact Us
Work With Us
CareersAffiliate
TipRanks For Business
For BrokersFor Hedge FundsFor Investment AdvisorsFor Academic Research
Company Policy
FAQPrivacy PolicyTerms of UseEducation Center
Follow Us On
YouTubeTwitterStocktwitsFacebookInstagramLinkedin
About Us
Plans & Pricing
Welcome
LoginSign Up
Research Tools
Top Smart Score StocksAnalysts' Top StocksInsiders' Hot StocksTrending Stocks
HomeMarket NewsStock AnalysisTipRanks LabsIdeas & Insights
Daily Stock RatingsDaily Insider Transactions
Expert CenterTop Wall Street AnalystsTop Financial BloggersTop Corporate InsidersTop Hedge Fund ManagersTop Individual InvestorsTop Performing Research Firms
Stock ComparisonAirline StocksBank StocksBiotech StocksBitcoin StocksCannabis StocksCasino StocksCoronavirus Therapeutics StocksCoronavirus Vaccine StocksCryptocurrency StocksElectric Vehicles StocksFAANG StocksHealthcare StocksHigh Dividend StocksHotel StocksLarge Cap StocksMega Cap StocksNFT StocksOil StocksOutdoor Activities StocksStay-At-Home StocksWallStreetBets StocksWork-From-Home Stocks
Stock ScreenerPenny Stocks
Dividend Calculator
Earnings CalendarsDividend CalendarsStock Market HolidaysIPO Calendar
Smart Portfolio
Account & More
Heron Therapeutics (HRTX)
NASDAQ:HRTX
HRTXHeron Therapeutics
$12.02
-$0.08 (-0.66%)
Stock AnalysisAnalystsRisk Factors
New
InvestorsBloggersInsidersNewsHedge Funds
Fundamentals
Chartsearningsdividendssimilar
Actions

Heron Therapeutics Stock Analysis & Ratings

Heron Therapeutics Stock Analysis Overview

Smart Score
6
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score

ANALYST RATINGS

CONSENSUS
Strong Buy
Average Price Target : $27.50

BLOGGER OPINIONS

SENTIMENT
Bullish
HRTX Sentiment 100% Sector Average 71%

HEDGE FUND ACTIVITY

TREND
▲ Increased
By 185.0 Shares Last Quarter.

INSIDER ACTIVITY

TREND
N/A
Currently Not Enough Data Available

TIPRANKS INVESTORS

SENTIMENT
Very Positive
Last 7 Days ▲3.5% Last 30 Days ▲13.2%

NEWS SENTIMENT

LAST 7 DAYS
N/A
Currently Not Enough Data Available

TECHNICALS

SMA
Negative
20 days / 200 days
MOMENTUM
-25.44%
12 Months Change

FUNDAMENTALS

RETURN ON EQUITY
-96.72%
Trailing 12 Months
ASSET GROWTH
-6.58%
Trailing 12 Months
The Heron Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Top Smart Score Stocks >

Stock Chart

HRTX
HRTX Advanced Chart >

HRTX Stock Stats

Previous Close$12.1
Open$11.86
Bid12.01 x 300
Ask12.03 x 105
Today’s Range$11.82 - $12.2
52-Week Range$10.10 - $22.40
Volume293.20K
Average Volume1.63M
Market Cap$1.22B
Beta1.39
P/E Ratio-4.8
EPS-2.52
Earnings DateNov 10, 2021
Dividend & YieldN/A
Ex-Dividend DateN/A
1Y Price Target$27.50

Company Description

Heron Therapeutics

Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
Sector
Healthcare
Industry
Biotechnology
CEO
Barry D. Quart
Employees
223
Website
http://www.herontx.com
ISIN
US4277461020
Address
4242 Campus Point Court, San Diego, CA, 92121, US

Financials

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

Heron Therapeutics News

2 “Strong Buy” Stocks With Heavy Short Interest
2 “Strong Buy” Stocks With Heavy Short Interest
Right now, markets are giving investors opposing trends simultaneously. The S&P and NASDAQ have posted strong year-to-date gains....
CRSRHRTX
2 “Strong Buy” Biotech Stocks With Major Catalysts Approaching
2 “Strong Buy” Biotech Stocks With Major Catalysts Approaching
For investors seeking a strong growth option, and willing to take on some added risk, the biotech sector...
ARDXHRTX
Heron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst
Heron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst
It was a difficult start to the week for Heron Therapeutics (HRTX). Monday saw shares plunge after the...
HRTX
Billionaire Jim Simons Pulls the Trigger on These 3 Healthcare Stocks
Billionaire Jim Simons Pulls the Trigger on These 3 Healthcare Stocks
Despite COVID-19’s devastating impact, one legendary stock picker might have just cracked the market code. While the broader...
AUPHDRRXHRTX
See more HRTX news >

HRTX FAQ

What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest stock price was $10.10 and its highest was $22.40 in the past 12 months.
    What is Heron Therapeutics’s market cap?
    Heron Therapeutics’s market cap is $1.22B.
      What is Heron Therapeutics’s price target?
      The average price target for Heron Therapeutics is $27.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $35.00 ,the lowest forecast is $24.00. The average price target represents 128.79% Increase from the current price of $12.02.
        What do analysts say about Heron Therapeutics?
        Heron Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Heron Therapeutics’s upcoming earnings report date?
          Heron Therapeutics’s upcoming earnings report date is Nov 10, 2021 which is in 2 months.
            How were Heron Therapeutics’s earnings last quarter?
            Heron Therapeutics released its earnings results on Aug 09, 2021. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.558 by -$0.062.
              Is Heron Therapeutics overvalued?
              According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued.
                Does Heron Therapeutics pay dividends?
                Heron Therapeutics does not currently pay dividends.
                What is Heron Therapeutics’s EPS estimate?
                Heron Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Heron Therapeutics have?
                Heron Therapeutics has 101,910,000 shares outstanding.
                  What happened to Heron Therapeutics’s price movement after its last earnings report?
                  Heron Therapeutics reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.558. Following the earnings report the stock price went down -0.339%.
                    Which hedge fund is a major shareholder of Heron Therapeutics?
                    Among the largest hedge funds holding Heron Therapeutics’s share is Fisher Asset Management LLC. It holds Heron Therapeutics’s shares valued at 542K.

                      Get More with TipRanks Premium

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis
                      Only $29.95/Month
                      Subscribe NowSee Plans & Pricing